Dr. Reddy’s Laboratories reported consolidated revenue of ₹87.53 billion in Q3 FY26, surpassing IBES estimates of ₹83.81 billion. Net profit stood at ₹12.1 billion, ahead of the expected ₹10.7 billion, despite a one-time charge of ₹1.17 billion related to labour codes. Strong operational performance drove the earnings beat.
Dr. Reddy’s Laboratories has announced its Q3 FY26 results, delivering a robust performance that exceeded market expectations. The company recorded consolidated revenue from operations of ₹87.53 billion, well above analyst estimates of ₹83.81 billion.
Net profit came in at ₹12.1 billion, beating the IBES forecast of ₹10.7 billion. This was achieved despite a quarterly charge of ₹1.17 billion linked to compliance with India’s new labour codes. The results highlight Dr. Reddy’s ability to sustain profitability while navigating regulatory costs.
The company’s strong showing underscores its resilience in the face of rising compliance expenses and positions it favorably in the competitive pharmaceutical landscape.
Key Highlights
-
Revenue from Operations: ₹87.53 billion (vs. estimate ₹83.81 billion)
-
Net Profit: ₹12.1 billion (vs. estimate ₹10.7 billion)
-
Labour Code Impact: One-time charge of ₹1.17 billion
-
Performance Driver: Strong operational efficiency and market demand
-
Outlook: Continued focus on compliance, innovation, and global expansion
Dr. Reddy’s results reaffirm its standing as one of India’s leading pharmaceutical companies, balancing regulatory obligations with growth momentum.
Sources: Reuters, Business Standard, Moneycontrol